Skip to content

Ramucirumab

Cyramza (ramucirumab) is an antibody pharmaceutical. Ramucirumab was first approved as Cyramza on 2014-04-21. It is used to treat colorectal neoplasms, non-small-cell lung carcinoma, and stomach neoplasms in the USA. It has been approved in Europe to treat stomach neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2.
Trade Name Cyramza
Common Name Ramucirumab
Indication colorectal neoplasms, non-small-cell lung carcinoma, stomach neoplasms
Drug Class Monoclonal antibodies
Ramucirumab
Get full access now